Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05391724 · ClinicalTrials.gov registry record · Phase 1
Safety and Pharmacokinetics of CMX001 in Impaired Hepatic Function and Healthy Subjects
A Phase 1 study, sponsored by Jazz Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
NCT05391724 is a Phase 1 study that has completed, run by Jazz Pharmaceuticals. The registered enrollment target is 25 participants.
The verdict
NCT05391724, a Phase 1 study, has completed, sponsored by Jazz Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
This is an open-label, non-randomized, multi-center, sequential group, safety, tolerance, and Pharmacokinetic study of a single dose of CMX001 administered at 2 mg/kg of ideal body weight rounded to the closest 20 mg in fasted healthy control subjects compared with that in fasted subjects with moderate and severe hepatic impairment.
Interventions
- DRUG CMX001
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2011-02 |
| Est. Completion | 2011-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05391724
The ClinicalTrials.gov registry entry for NCT05391724 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Jazz Pharmaceuticals, which has 128 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CMX001 is the first listed.
NCT05391724 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05391724 about?
NCT05391724 is a clinical study titled "Safety and Pharmacokinetics of CMX001 in Impaired Hepatic Function and Healthy Subjects". This is an open-label, non-randomized, multi-center, sequential group, safety, tolerance, and Pharmacokinetic study of a single dose of CMX001 administered at 2 mg/kg of ideal body weight rounded to the closest 20 mg in fasted healthy control subjects compared with that in fasted subjects with moder...
What is the current status of trial NCT05391724?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2011-02. Estimated completion is 2011-09.
What interventions are being tested in trial NCT05391724?
The interventions under investigation include: CMX001 (DRUG).
Who is sponsoring clinical trial NCT05391724?
This trial is sponsored by Jazz Pharmaceuticals, which has 128 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.